Table 1 Characteristics of patients (n, %).
Characteristics | Total | Combined with anti-angiogenosis group | Non-combined with anti-angiogenosis group | χ2 | P |
|---|---|---|---|---|---|
Total | 190 | 96 | 94 | Â | Â |
Sex | Â | Â | Â | 0.566 | 0.452 |
 Male | 142 (74.7) | 74 (77.1) | 68 (72.3) |  |  |
Female | 48 (25.3) | 22 (22.9) | 26 (27.7) | Â | Â |
Age, years | Â | Â | Â | 0.52 | 0.471 |
 ≥ 65 | 92 (48.4) | 44 (45.8) | 48 (59.6) |  |  |
 < 65 | 98 (51.6) | 52 (54.2) | 46 (40.4) |  |  |
Histology | Â | Â | Â | 0.965 | 0.617 |
 Adenocarcinoma | 120 (63.2) | 61 (63.5) | 59 (62.8) |  |  |
 Squamous cell carcinomas | 42 (22.1) | 23 (24.0) | 19 (20.2) |  |  |
 Other | 28 (14.7) | 12 (12.5) | 16 (17.0) |  |  |
Disease stage at diagnosis | Â | Â | Â | 0.445 | 0.505 |
 III | 29 (15.3) | 13 (13.5) | 16 (17.0) |  |  |
 IV | 161 (84.7) | 83 (86.5) | 78 (83.0) |  |  |
PS score | Â | Â | Â | 0.73 | 0.393 |
 0–1 | 168 (88.4) | 83 (86.5) | 85 (90.4) |  |  |
 ≥ 2 | 22 (11.6) | 13 (13.5) | 9 (9.6) |  |  |
EGFR mutation status | Â | Â | Â | 4.394 | 0.111 |
 Negative | 89 (46.8) | 52 (54.2) | 37 (39.4) |  |  |
 Positive | 41 (21.6) | 19 (19.8) | 22 (23.4) |  |  |
 Unknown | 60 (31.6) | 25 (26.0) | 35 (37.2) |  |  |
Line of therapy | Â | Â | Â | 0.317 | 0.573 |
 1 | 65 (34.2) | 31 (32.3) | 34 (36.3) |  |  |
 ≥ 2 | 125 (65.8) | 65 (67.7) | 60 (63.8) |  |  |
PD-L1 TPS | Â | Â | Â | 1.23 | 0.746 |
 ≥ 50% | 30 (15.8) | 13 (13.5) | 17 (18.1) |  |  |
 1–49% | 18 (9.5) | 10 (10.4) | 8 (8.5) |  |  |
 < 1% | 20 (10.5) | 9 (9.4) | 11 (11.7) |  |  |
 Unknown | 122 (64.2) | 64 (66.7) | 58 (61.7) |  |  |
